tiprankstipranks
Advertisement
Advertisement

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

Story Highlights
  • China NT Pharma revealed that former independent director Ng Ming Kwan resigned after claiming he was not properly informed about key past transactions and related compliance issues.
  • Ng criticized the accuracy of past disclosures and governance processes, while the board disputed his views but pledged to review the matters and issue further clarifications if needed.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

Meet Samuel – Your Personal Investing Prophet

China NT Pharma Group Co., Ltd. ( (HK:1011) ) just unveiled an update.

China NT Pharma Group Co., Ltd. disclosed further details following the earlier resignation of independent non-executive director Mr. Ng Ming Kwan. The board said it received a written statement from Mr. Ng on 18 May 2026, after his resignation and the initial announcement, outlining disagreements that he believes should be drawn to shareholders’ attention.

Mr. Ng argued he was not properly informed of, or involved in, certain historic and recent transactions that may have constituted notifiable or connected transactions under Hong Kong’s Listing Rules. He said he only became aware of these matters and related compliance issues shortly before the company published its announcement on past transactions on 8 May 2026.

In his statement, Mr. Ng contended that the past transactions announcement misrepresented his awareness and involvement, and that he should not be held responsible for those matters. He also raised concerns over the accuracy and adequacy of disclosure, particularly regarding the identification of non-compliances, attribution of responsibility and the description of remedial measures.

Mr. Ng further claimed he was asked to approve the past transactions announcement without being given sufficient information or documentation, and that his requests for more details were not addressed before publication. He cited weaknesses in internal governance, compliance processes and board-level information flow, stating that these conditions prevented him from satisfactorily discharging his duties and led to his resignation.

The board stressed that Mr. Ng’s written statement reflects his position only and that it does not necessarily agree with his views. The company said it is reviewing the issues he raised and will provide additional information or clarification where appropriate, signaling potential ongoing governance and compliance scrutiny that may be closely watched by investors and regulators.

More about China NT Pharma Group Co., Ltd.

China NT Pharma Group Co., Ltd. is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 1011. The group is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical listed-company structure subject to Hong Kong Listing Rules and corporate governance requirements.

Average Trading Volume: 313,467

Technical Sentiment Signal: Sell

Current Market Cap: HK$578.9M

Find detailed analytics on 1011 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1